Tiffany le

Tiffany Le is a Principal at New Enterprise Associates (NEA), based in San Francisco, CA, where she leads investments in the life sciences sector, with a specialized focus on medtech, healthtech, and innovations at the intersection of technology and medicine. She actively serves as a Board Director for multiple companies including Allay Therapeutics, Amber Therapeutics, FIRE1, Magenta Medical, Revelle Aesthetics, and ExploraMed, and works closely with Moximed, Setpoint Medical, and Willow.

Prior to joining NEA, Tiffany built a decade of experience in healthcare investments and strategic consulting, holding senior roles at Kaiser Permanente Ventures and L.E.K. Consulting, where she focused on life sciences projects for leading healthcare organizations. Her career is defined by deep expertise in evaluating cutting-edge medical technologies and supporting portfolio companies to achieve clinical and commercial milestones.

Tiffany holds a BA in Business Economic Theory from UCLA and an MBA from Harvard Business School, bringing a blend of analytical rigor and sector insight to her role. She is recognized for her conviction-driven investment approach, especially in backing novel and high-impact health technologies that address significant market needs.